US20010025035A1 - Water soluble prodrugs of hindered alcohols - Google Patents
Water soluble prodrugs of hindered alcohols Download PDFInfo
- Publication number
- US20010025035A1 US20010025035A1 US09/733,817 US73381700A US2001025035A1 US 20010025035 A1 US20010025035 A1 US 20010025035A1 US 73381700 A US73381700 A US 73381700A US 2001025035 A1 US2001025035 A1 US 2001025035A1
- Authority
- US
- United States
- Prior art keywords
- compound
- group
- formula
- compound according
- camptothecin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C[C@](C(C=C1*2CC3C=C(C=CC=C4)C4=*C13)=C(CO1)C2=O)(C1=O)O Chemical compound C[C@](C(C=C1*2CC3C=C(C=CC=C4)C4=*C13)=C(CO1)C2=O)(C1=O)O 0.000 description 15
- FYNFRMRJGQZHCO-NRFANRHFSA-N CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O Chemical compound CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O FYNFRMRJGQZHCO-NRFANRHFSA-N 0.000 description 3
- CAKGZJXNQBBWES-VBGIGSMRSA-E C.C/C=C/CC(C)C(OCOP(=O)(O[Y])O[Y])C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O[Y])O[Y].CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O[Y])O[Y].CC[C@@]1(OCOP(C)(=O)O[Y])C(=O)OCC2=C1C=C1C3N=C4C=CC=CC4=CC3CN1C2=O.COC1=CC([C@@H]2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3CCC(=O)[C@@H]32)OCO4)=CC(OC)=C1OCOP(=O)(O[Y])O[Y] Chemical compound C.C/C=C/CC(C)C(OCOP(=O)(O[Y])O[Y])C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O[Y])O[Y].CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O[Y])O[Y].CC[C@@]1(OCOP(C)(=O)O[Y])C(=O)OCC2=C1C=C1C3N=C4C=CC=CC4=CC3CN1C2=O.COC1=CC([C@@H]2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3CCC(=O)[C@@H]32)OCO4)=CC(OC)=C1OCOP(=O)(O[Y])O[Y] CAKGZJXNQBBWES-VBGIGSMRSA-E 0.000 description 2
- JPYAPRAKHZCPAU-SFVMKZFCSA-N CC[C@@]1(O)C(=O)OCC2=C1C=C1C3N=C4C=CC=CC4=CC3CN1C2=O Chemical compound CC[C@@]1(O)C(=O)OCC2=C1C=C1C3N=C4C=CC=CC4=CC3CN1C2=O JPYAPRAKHZCPAU-SFVMKZFCSA-N 0.000 description 2
- UWILSJYOVXOHTR-IECDAOIRSA-N CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(C)(C)=O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O Chemical compound CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(C)(C)=O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O UWILSJYOVXOHTR-IECDAOIRSA-N 0.000 description 2
- UWILSJYOVXOHTR-IECDAOIRSA-L CC[C@@]1(OCOP(=O)([O-])[O-])C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(C)(C)=O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[Na+].[Na+] Chemical compound CC[C@@]1(OCOP(=O)([O-])[O-])C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(C)(C)=O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[Na+].[Na+] UWILSJYOVXOHTR-IECDAOIRSA-L 0.000 description 2
- JOOIUUXKTMYVOG-YOVULPASSA-N C.C/C=C/CC(C)C(OCSC)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.CC[C@@]1(OCSC)C(=O)OCC2=C1C=C1C3N=C4C=CC=CC4=CC3CN1C2=O.COC1=CC([C@@H]2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3CCC(=O)[C@@H]32)OCO4)=CC(OC)=C1OCSC.CSCOC1=C(C(C)C)C=CC=C1C(C)C.CSCOC1=C(C)C(C)=C2OC(C)(CCCC(C)CCCC(C)CCCC(C)C)CCC2=C1C Chemical compound C.C/C=C/CC(C)C(OCSC)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.CC[C@@]1(OCSC)C(=O)OCC2=C1C=C1C3N=C4C=CC=CC4=CC3CN1C2=O.COC1=CC([C@@H]2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3CCC(=O)[C@@H]32)OCO4)=CC(OC)=C1OCSC.CSCOC1=C(C(C)C)C=CC=C1C(C)C.CSCOC1=C(C)C(C)=C2OC(C)(CCCC(C)CCCC(C)CCCC(C)C)CCC2=C1C JOOIUUXKTMYVOG-YOVULPASSA-N 0.000 description 1
- WQTXAASWMLLBNF-DJYJFFGHSA-N C.COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O.COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(C)=O.CP(C)(=O)OCCl Chemical compound C.COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1O.COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(C)=O.CP(C)(=O)OCCl WQTXAASWMLLBNF-DJYJFFGHSA-N 0.000 description 1
- MXTMNFZELVUWQV-MDZDMXLPSA-N C/C=C/CC(C)C(O)C(C(=O)NC)N(C)C(=O)C(C(C)C)N(C)C Chemical compound C/C=C/CC(C)C(O)C(C(=O)NC)N(C)C(=O)C(C(C)C)N(C)C MXTMNFZELVUWQV-MDZDMXLPSA-N 0.000 description 1
- CMINPSDYOTXDFS-ITFLXOGHSA-N C/C=C/CC(C)C(O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.C/C=C/CC(C)C(OCSC)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C Chemical compound C/C=C/CC(C)C(O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.C/C=C/CC(C)C(OCSC)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C CMINPSDYOTXDFS-ITFLXOGHSA-N 0.000 description 1
- QQYROPXHDXWSTQ-BQYQJAHWSA-N C/C=C/CC(C)C(OCOP(=O)(O)O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C Chemical compound C/C=C/CC(C)C(OCOP(=O)(O)O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C QQYROPXHDXWSTQ-BQYQJAHWSA-N 0.000 description 1
- GGTDMLNPSWLDKV-YBMUDJIRSA-N C/C=C/CC(C)C(OCOP(=O)(O)O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.C/C=C/CC(C)C(OCOP(C)(C)=O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C Chemical compound C/C=C/CC(C)C(OCOP(=O)(O)O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.C/C=C/CC(C)C(OCOP(C)(C)=O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C GGTDMLNPSWLDKV-YBMUDJIRSA-N 0.000 description 1
- OGOAUNRNZNQCJV-WYDMODLRSA-N C/C=C/CC(C)C(OCOP(C)(C)=O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.C/C=C/CC(C)C(OCSC)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.CP(C)(=O)O Chemical compound C/C=C/CC(C)C(OCOP(C)(C)=O)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.C/C=C/CC(C)C(OCSC)C1C(=O)NCCCCN(C)C(C(C)C)C(=O)N1C.CP(C)(=O)O OGOAUNRNZNQCJV-WYDMODLRSA-N 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)C)=C1O Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- JXQUGCXHWCOHMZ-UHFFFAOYSA-M CC(C)C1=CC=CC(C(C)C)=C1O.CC(C)C1=CC=CC(C(C)C)=C1OCCl.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O[Ag-2].ClCI Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O.CC(C)C1=CC=CC(C(C)C)=C1OCCl.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O[Ag-2].ClCI JXQUGCXHWCOHMZ-UHFFFAOYSA-M 0.000 description 1
- MAXXOXCKIHNYHY-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)C)=C1O.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)OCCl Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)OCCl MAXXOXCKIHNYHY-UHFFFAOYSA-N 0.000 description 1
- PHBXCZBUPIZKSU-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)C)=C1O.CSCCl.CSCOC1=C(C(C)C)C=CC=C1C(C)C.[NaH] Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O.CSCCl.CSCOC1=C(C(C)C)C=CC=C1C(C)C.[NaH] PHBXCZBUPIZKSU-UHFFFAOYSA-N 0.000 description 1
- OBHDEDRFRJIWLK-UHFFFAOYSA-M CC(C)C1=CC=CC(C(C)C)=C1OCCl.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O[Ag-2] Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCCl.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O[Ag-2] OBHDEDRFRJIWLK-UHFFFAOYSA-M 0.000 description 1
- KQEJGQCIPKGGNR-UHFFFAOYSA-M CC(C)C1=CC=CC(C(C)C)=C1OCCl.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O[Ag-2].CSCOC1=C(C(C)C)C=CC=C1C(C)C.O=S(=O)(Cl)Cl Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCCl.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O[Ag-2].CSCOC1=C(C(C)C)C=CC=C1C(C)C.O=S(=O)(Cl)Cl KQEJGQCIPKGGNR-UHFFFAOYSA-M 0.000 description 1
- GISXYNZUVHUZLQ-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)C)=C1OCCl.CSCOC1=C(C(C)C)C=CC=C1C(C)C.O=S(=O)(Cl)Cl Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCCl.CSCOC1=C(C(C)C)C=CC=C1C(C)C.O=S(=O)(Cl)Cl GISXYNZUVHUZLQ-UHFFFAOYSA-N 0.000 description 1
- QVNNONOFASOXQV-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O)O Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O)O QVNNONOFASOXQV-UHFFFAOYSA-N 0.000 description 1
- OQLTXIYWKKSVOL-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O)O.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O)O.CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O OQLTXIYWKKSVOL-UHFFFAOYSA-N 0.000 description 1
- XTEZYBUOFVVTND-UHFFFAOYSA-L CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O[Na+])O[Na+].CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCOP(=O)(O[Na+])O[Na+].CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O XTEZYBUOFVVTND-UHFFFAOYSA-L 0.000 description 1
- NTCJSZUPQDDTRV-UHFFFAOYSA-M CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CC(C)C1=CC=CC(C(C)C)=C1O[Na+].CP(C)(=O)OCOP(C)(C)=O Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CC(C)C1=CC=CC(C(C)C)=C1O[Na+].CP(C)(=O)OCOP(C)(C)=O NTCJSZUPQDDTRV-UHFFFAOYSA-M 0.000 description 1
- XALLJFVRWFGKIN-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O.CSCOC1=C(C(C)C)C=CC=C1C(C)C Chemical compound CC(C)C1=CC=CC(C(C)C)=C1OCOP(C)(C)=O.CP(C)(=O)O.CSCOC1=C(C(C)C)C=CC=C1C(C)C XALLJFVRWFGKIN-UHFFFAOYSA-N 0.000 description 1
- QVNNONOFASOXQV-UHFFFAOYSA-L CC(C)c1cccc(C(C)C)c1OCOP(=O)([O-])[O-].[*+].[*+] Chemical compound CC(C)c1cccc(C(C)C)c1OCOP(=O)([O-])[O-].[*+].[*+] QVNNONOFASOXQV-UHFFFAOYSA-L 0.000 description 1
- DTTHRRULBRTNHD-UHFFFAOYSA-N CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O)O Chemical compound CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O)O DTTHRRULBRTNHD-UHFFFAOYSA-N 0.000 description 1
- LDBRPLZFGQOAJP-UHFFFAOYSA-N CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O)O.CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(C)(C)=O Chemical compound CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O)O.CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(C)(C)=O LDBRPLZFGQOAJP-UHFFFAOYSA-N 0.000 description 1
- IMROLBVZUPYGAD-UHFFFAOYSA-L CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O[Na])O[Na].CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(C)(C)=O Chemical compound CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(=O)(O[Na])O[Na].CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(C)(C)=O IMROLBVZUPYGAD-UHFFFAOYSA-L 0.000 description 1
- CRZXYXZHVNEHCU-UHFFFAOYSA-N CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(C)(C)=O.CP(C)(=O)OCCl Chemical compound CC1=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C(C)C(C)=C1OCOP(C)(C)=O.CP(C)(=O)OCCl CRZXYXZHVNEHCU-UHFFFAOYSA-N 0.000 description 1
- PCCUTAUNTMDRDB-UHFFFAOYSA-M CC1=CC=C(S(=O)O[O-])C=C1.CCOC=O.O=COCCl.[Ag] Chemical compound CC1=CC=C(S(=O)O[O-])C=C1.CCOC=O.O=COCCl.[Ag] PCCUTAUNTMDRDB-UHFFFAOYSA-M 0.000 description 1
- AYEHNNQTGGEUKB-UHFFFAOYSA-N CC=O.ClCI.O=COCCl Chemical compound CC=O.ClCI.O=COCCl AYEHNNQTGGEUKB-UHFFFAOYSA-N 0.000 description 1
- DVQRRJRRZNTVSF-UHFFFAOYSA-N CC=O.ICI.O=CCOC=O Chemical compound CC=O.ICI.O=CCOC=O DVQRRJRRZNTVSF-UHFFFAOYSA-N 0.000 description 1
- NTDBOPNXOOCTHP-UHFFFAOYSA-L CCC1(OCOP(=O)([O-])[O-])C(=O)OCc2c1cc1n(c2=O)CC2C=c3ccccc3=NC12.II.[*+].[*+] Chemical compound CCC1(OCOP(=O)([O-])[O-])C(=O)OCc2c1cc1n(c2=O)CC2C=c3ccccc3=NC12.II.[*+].[*+] NTDBOPNXOOCTHP-UHFFFAOYSA-L 0.000 description 1
- ZVLYSWHSKMJFQD-RMFCRPEKSA-N CC[C@@]1(O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCSC)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O Chemical compound CC[C@@]1(O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCSC)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O ZVLYSWHSKMJFQD-RMFCRPEKSA-N 0.000 description 1
- GRMZWRARSWKHOV-HRQBZJEISA-M CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CNCC(O)C(O)C(O)C(O)CO Chemical compound CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CNCC(O)C(O)C(O)C(O)CO GRMZWRARSWKHOV-HRQBZJEISA-M 0.000 description 1
- KCYHBELYFZTCEE-HRQBZJEISA-L CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.N=C(N)NCCCC(N)C(=O)[O-] Chemical compound CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.N=C(N)NCCCC(N)C(=O)[O-] KCYHBELYFZTCEE-HRQBZJEISA-L 0.000 description 1
- XIBUYSSBOSMHRJ-HRQBZJEISA-L CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.NCCCCC(N)C(=O)[O-] Chemical compound CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.NCCCCC(N)C(=O)[O-] XIBUYSSBOSMHRJ-HRQBZJEISA-L 0.000 description 1
- VSEWSLQHCRZBRJ-WBWGXLNPSA-M CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[Na+] Chemical compound CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[Na+] VSEWSLQHCRZBRJ-WBWGXLNPSA-M 0.000 description 1
- VSEWSLQHCRZBRJ-WBWGXLNPSA-L CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])[O-])C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[Na+].[Na+] Chemical compound CC[C@@]1(OCOP(=O)(O)O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCOP(=O)([O-])[O-])C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.[Na+].[Na+] VSEWSLQHCRZBRJ-WBWGXLNPSA-L 0.000 description 1
- PDUMXTUMJAMNOU-NGQCLHCUSA-N CC[C@@]1(OCOP(C)(C)=O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCSC)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CP(C)(=O)O Chemical compound CC[C@@]1(OCOP(C)(C)=O)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CC[C@@]1(OCSC)C(=O)OCC2=C1C=C1C3=NC4=C(C=CC=C4)C=C3CN1C2=O.CP(C)(=O)O PDUMXTUMJAMNOU-NGQCLHCUSA-N 0.000 description 1
- WNYKGTOBONPIFC-DHUJRADRSA-N CC[C@](C(C=C1N2Cc3cc(cccc4)c4nc13)=C(CO1)C2=O)(C1=O)OCOP(OCc1ccccc1)(OCc1ccccc1)=O Chemical compound CC[C@](C(C=C1N2Cc3cc(cccc4)c4nc13)=C(CO1)C2=O)(C1=O)OCOP(OCc1ccccc1)(OCc1ccccc1)=O WNYKGTOBONPIFC-DHUJRADRSA-N 0.000 description 1
- VQQPYVJJYMSMQA-DGDYHRPMSA-N COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(=O)(O)O Chemical compound COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(=O)(O)O VQQPYVJJYMSMQA-DGDYHRPMSA-N 0.000 description 1
- FSESVQJWSRYWMP-KWKDRTTFSA-N COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(=O)(O)O.COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(C)=O Chemical compound COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(=O)(O)O.COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(C)=O FSESVQJWSRYWMP-KWKDRTTFSA-N 0.000 description 1
- MKYOFAVHLFIEQZ-YLLAGIRRSA-M COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(=O)[O-].COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(C)=O.[Na+] Chemical compound COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(=O)[O-].COC1=CC(C2C3=CC4=C(C=C3C(OC3O[C@@H]5COC(C)OC5C(O)C3O)[C@H]3COC(=O)[C@H]23)OCO4)=CC(OC)=C1OCOP(C)(C)=O.[Na+] MKYOFAVHLFIEQZ-YLLAGIRRSA-M 0.000 description 1
- HVPSYBJIBKDUOM-UHFFFAOYSA-N CP(C)(=O)OCCl Chemical compound CP(C)(=O)OCCl HVPSYBJIBKDUOM-UHFFFAOYSA-N 0.000 description 1
- CHHJDCVKYCVTHD-UHFFFAOYSA-N O=COCCl Chemical compound O=COCCl CHHJDCVKYCVTHD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
- C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Compounds Of Unknown Constitution (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/733,817 US6451776B2 (en) | 1998-08-07 | 2000-12-08 | Water soluble prodrugs of hindered alcohols |
US10/208,647 US6872838B2 (en) | 1998-08-07 | 2002-07-29 | Water soluble prodrugs of hindered alcohols |
US10/991,348 US7244718B2 (en) | 1998-08-07 | 2004-11-17 | Water soluble prodrugs of hindered alcohols |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/131,385 US6204257B1 (en) | 1998-08-07 | 1998-08-07 | Water soluble prodrugs of hindered alcohols |
US09/733,817 US6451776B2 (en) | 1998-08-07 | 2000-12-08 | Water soluble prodrugs of hindered alcohols |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/131,385 Division US6204257B1 (en) | 1998-08-07 | 1998-08-07 | Water soluble prodrugs of hindered alcohols |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/208,647 Division US6872838B2 (en) | 1998-08-07 | 2002-07-29 | Water soluble prodrugs of hindered alcohols |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010025035A1 true US20010025035A1 (en) | 2001-09-27 |
US6451776B2 US6451776B2 (en) | 2002-09-17 |
Family
ID=22449234
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/131,385 Expired - Lifetime US6204257B1 (en) | 1998-08-07 | 1998-08-07 | Water soluble prodrugs of hindered alcohols |
US09/733,817 Expired - Lifetime US6451776B2 (en) | 1998-08-07 | 2000-12-08 | Water soluble prodrugs of hindered alcohols |
US10/208,647 Expired - Fee Related US6872838B2 (en) | 1998-08-07 | 2002-07-29 | Water soluble prodrugs of hindered alcohols |
US10/991,348 Expired - Fee Related US7244718B2 (en) | 1998-08-07 | 2004-11-17 | Water soluble prodrugs of hindered alcohols |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/131,385 Expired - Lifetime US6204257B1 (en) | 1998-08-07 | 1998-08-07 | Water soluble prodrugs of hindered alcohols |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/208,647 Expired - Fee Related US6872838B2 (en) | 1998-08-07 | 2002-07-29 | Water soluble prodrugs of hindered alcohols |
US10/991,348 Expired - Fee Related US7244718B2 (en) | 1998-08-07 | 2004-11-17 | Water soluble prodrugs of hindered alcohols |
Country Status (27)
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050107385A1 (en) * | 2003-09-09 | 2005-05-19 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
US20060041011A1 (en) * | 2004-07-12 | 2006-02-23 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
US20060100160A1 (en) * | 2004-07-12 | 2006-05-11 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
US20060205969A1 (en) * | 2004-12-23 | 2006-09-14 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
US20080221069A1 (en) * | 2005-09-02 | 2008-09-11 | Auspex Pharmaceuticals, Inc. | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
US20080234229A1 (en) * | 2005-08-18 | 2008-09-25 | Auspex Pharmaceuticals, Inc. | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
US20080248093A1 (en) * | 2003-10-24 | 2008-10-09 | Auspex Pharmaceuticals, Inc. | pH sensitive prodrugs of 2,6-diisopropylphenol |
EP2292577A1 (en) | 2007-05-09 | 2011-03-09 | Pharmacofore, Inc. | (+)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof |
EP2392559A1 (en) | 2007-05-09 | 2011-12-07 | Pharmacofore, Inc. | Therapeutic compounds |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
WO2000010531A1 (en) * | 1998-08-19 | 2000-03-02 | Rtp Pharma Inc. | Injectable aqueous dispersions of propofol |
US6362172B2 (en) * | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
US6362234B1 (en) * | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
US6448401B1 (en) * | 2000-11-20 | 2002-09-10 | Bristol-Myers Squibb Company | Process for water soluble azole compounds |
AU2002245996B8 (en) * | 2001-04-20 | 2005-07-14 | Ophthalmopharma Ag | Modified cyclosporine which can be used as a pro-drug and use thereof |
AU2002334675A1 (en) * | 2001-09-26 | 2003-04-07 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
CA2470423C (en) * | 2001-12-21 | 2011-03-15 | Guilford Pharmaceuticals, Inc. | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
HU229293B1 (hu) * | 2001-12-28 | 2013-10-28 | Eisai Inc | Propofol vízoldható elõgyógyszerét tartalmazó vizes alapú gyógyászati készítmények |
KR20070087004A (ko) * | 2002-04-08 | 2007-08-27 | 엠쥐아이 쥐피, 아이엔씨. | 프로포폴의 수용성 프로드럭을 함유하는 약제학적 조성물및 그것을 투여하는 방법 |
ITRM20020306A1 (it) | 2002-05-31 | 2003-12-01 | Sigma Tau Ind Farmaceuti | Esteri in posizione 20 di camptotecine. |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
ZA200504940B (en) * | 2003-01-28 | 2006-09-27 | Xenoport Inc | Amino acid derived prodrugs of propofol, compositions and uses thereof |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
US7834043B2 (en) * | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
AU2004299109A1 (en) * | 2003-12-17 | 2005-06-30 | Eisai Inc. | Methods of administering water-soluble prodrugs of propofol for extended sedation |
CN102174076A (zh) | 2004-04-15 | 2011-09-07 | 普罗特奥里克斯公司 | 用于抑制蛋白酶体酶的化合物 |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
PL2030981T3 (pl) * | 2004-05-10 | 2014-12-31 | Onyx Therapeutics Inc | Związki do enzymatycznej inhibicji proteasomu |
WO2005111009A2 (en) * | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
EP2336138A3 (en) * | 2004-07-06 | 2011-11-16 | Abbott Laboratories | Prodrugs of HIV protease inhibitors |
US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
WO2006027711A2 (en) * | 2004-08-26 | 2006-03-16 | Nicholas Piramal India Limited | Prodrugs and codrugs containing bio- cleavable disulfide linkers |
EP1791521A4 (en) * | 2004-09-17 | 2009-10-21 | Eisai Corp North America | METHODS OF ADMINISTERING PROPOFOL PROMOTERS WITH WATER SOLUBLE |
WO2006133506A1 (en) | 2005-06-17 | 2006-12-21 | Vital Health Sciences Pty Ltd | A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
AU2006268326A1 (en) * | 2005-07-12 | 2007-01-18 | Eisai Inc. | Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation |
ES2441608T3 (es) | 2005-08-18 | 2014-02-05 | Zimmer Gmbh | Artículos de polietileno de peso molecular ultra-alto y métodos para formar artículos de polietileno de peso molecular ulra-alto |
JP4981673B2 (ja) * | 2005-09-13 | 2012-07-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法 |
PT1948678E (pt) * | 2005-11-09 | 2013-07-16 | Onyx Therapeutics Inc | Compostos para inibição de enzimas |
US7691852B2 (en) * | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
AU2007307301A1 (en) * | 2006-10-05 | 2008-04-17 | Eisai Inc. | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
US20080161400A1 (en) * | 2006-10-26 | 2008-07-03 | Xenoport, Inc. | Use of forms of propofol for treating diseases associated with oxidative stress |
ATE544476T1 (de) | 2007-04-10 | 2012-02-15 | Zimmer Inc | Antioxidans-stabilisiertes vernetztes ultrahochmolekulares polyethylen für anwendungen in medizinprodukten |
US8664290B2 (en) | 2007-04-10 | 2014-03-04 | Zimmer, Inc. | Antioxidant stabilized crosslinked ultra-high molecular weight polyethylene for medical device applications |
WO2008157627A1 (en) * | 2007-06-21 | 2008-12-24 | Xenoport, Inc. | Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus |
FI20070574A0 (fi) * | 2007-07-30 | 2007-07-30 | Kuopion Yliopisto | Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke |
EP2188870A1 (en) * | 2007-09-13 | 2010-05-26 | Aerosat Corporation | Communication system with broadband antenna |
US8427384B2 (en) | 2007-09-13 | 2013-04-23 | Aerosat Corporation | Communication system with broadband antenna |
US20090076141A1 (en) * | 2007-09-14 | 2009-03-19 | Xenoport, Inc. | Use of Propofol Prodrugs for Treating Neuropathic Pain |
US20090075947A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched fospropofol |
KR20170040374A (ko) * | 2007-10-04 | 2017-04-12 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
US20090098209A1 (en) * | 2007-10-15 | 2009-04-16 | University Of Kansas | Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration |
WO2009120162A1 (ru) * | 2008-03-25 | 2009-10-01 | Zhukovskij Oleg Igorevich | Субстанция "ua' orion" |
US20110212926A1 (en) * | 2008-05-20 | 2011-09-01 | Neurogesx, Inc. | Water-soluble acetaminophen analogs |
CA2724881C (en) | 2008-05-20 | 2016-09-27 | Neurogesx, Inc. | Carbonate prodrugs and methods of using the same |
US20100069441A1 (en) | 2008-09-02 | 2010-03-18 | Mikhail Fedorovich Gordeev | Antimicrobial indoline compounds for treatment of bacterial infections |
MX2011004225A (es) | 2008-10-21 | 2011-06-21 | Onyx Therapeutics Inc | Terapia de combinacion con epoxicetonas peptidicas. |
CN101798302B (zh) | 2009-02-06 | 2014-11-05 | 上海盟科药业有限公司 | 抗生素类药物1-(邻-氟苯基)二氢吡啶酮的合成及生产的方法和工艺 |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
CN101845057B (zh) * | 2009-03-27 | 2013-10-23 | 四川大学 | 取代苯酚的甲缩醛磷酸盐麻醉镇静药用化合物及制备方法 |
GB0905834D0 (en) | 2009-04-03 | 2009-05-20 | Seps Pharma Nv | Phosphonyl-containing phenolic derivatives useful as medicaments |
WO2010129918A1 (en) * | 2009-05-07 | 2010-11-11 | Regents Of The University Of Minnesota | Triptolide prodrugs |
US9150600B2 (en) | 2009-05-07 | 2015-10-06 | Regents Of The University Of Minnesota | Triptolide prodrugs |
CN101648973B (zh) * | 2009-09-03 | 2012-05-30 | 漆又毛 | 水溶性紫杉烷及制备方法 |
WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
CN102153607B (zh) * | 2010-02-11 | 2015-07-15 | 湖南方盛华美医药科技有限公司 | 水溶性喜树碱衍生物及包含其的药物组合物 |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
RU2553350C2 (ru) | 2010-03-30 | 2015-06-10 | Фосфейдженикс Лимитед | Трансдермальные пластыри |
US8697646B2 (en) | 2010-04-07 | 2014-04-15 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
US8399535B2 (en) * | 2010-06-10 | 2013-03-19 | Zimmer, Inc. | Polymer [[s]] compositions including an antioxidant |
US20120065170A1 (en) | 2010-09-10 | 2012-03-15 | Micurx Pharmaceuticals, Inc. | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections |
US8609637B2 (en) * | 2010-12-02 | 2013-12-17 | The University Of Kansas | Prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-(1H)-one and derivatives thereof |
WO2012122586A1 (en) | 2011-03-15 | 2012-09-20 | Phosphagenics Limited | New composition |
ITMI20110580A1 (it) * | 2011-04-08 | 2012-10-09 | Chemelectiva S R L | Iintermedi utili per la preparazione di fospropofol e processo per la loro preparazione |
UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
WO2013044064A1 (en) | 2011-09-22 | 2013-03-28 | Neurogesx, Inc. | Acetaminophen conjugates, compositions and methods of use thereof |
CN102516258B (zh) * | 2011-11-11 | 2014-06-25 | 正大天晴药业集团股份有限公司 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
CN102382133B (zh) * | 2011-12-02 | 2016-03-23 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠的制备及纯化方法 |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
US9580459B2 (en) * | 2013-04-26 | 2017-02-28 | Metselex, Inc. | Water-soluble ursodeoxycholic acid prodrugs |
WO2015050851A1 (en) | 2013-10-01 | 2015-04-09 | Zimmer, Inc. | Polymer compositions comprising one or more protected antioxidants |
WO2015117024A1 (en) * | 2014-01-31 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Novel therapeutics for the treatment of glaucoma |
CN105612166B (zh) | 2014-02-21 | 2019-02-19 | 上海盟科药业有限公司 | 治疗用水溶性(o-羰基)氨基磷酸酯前药 |
WO2015138137A1 (en) | 2014-03-12 | 2015-09-17 | Zimmer, Inc. | Melt-stabilized ultra high molecular weight polyethylene and method of making the same |
PT3209302T (pt) | 2014-10-21 | 2019-07-19 | Abbvie Inc | Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson |
WO2016090084A1 (en) | 2014-12-03 | 2016-06-09 | Zimmer, Inc. | Antioxidant-infused ultra high molecular weight polyethylene |
CN106674269A (zh) * | 2015-11-11 | 2017-05-17 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠四水合物及晶型及其制备方法和用途 |
CN106674268A (zh) * | 2015-11-11 | 2017-05-17 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠三水合物及晶型及其制备方法和用途 |
CN106674270A (zh) * | 2015-11-11 | 2017-05-17 | 陕西合成药业股份有限公司 | 一种磷丙泊酚钠无水合物及晶型及其制备方法和用途 |
CN108601732A (zh) | 2015-12-09 | 2018-09-28 | 磷肌酸有限公司 | 药物制剂 |
WO2017147146A1 (en) * | 2016-02-23 | 2017-08-31 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists |
JP2019515908A (ja) * | 2016-04-20 | 2019-06-13 | アッヴィ・インコーポレイテッド | カルビドパ及びl−ドパプロドラッグ並びに使用方法 |
US11331271B2 (en) * | 2016-05-27 | 2022-05-17 | The Johns Hopkins University | Buccal, sublingual and intranasal delivery of fospropofol |
WO2018017518A2 (en) | 2016-07-21 | 2018-01-25 | Astronics Aerosat Corporation | Multi-channel communications antenna |
US20190330260A1 (en) | 2016-12-21 | 2019-10-31 | Avecho Biotechnology Limited | Process |
US10992052B2 (en) | 2017-08-28 | 2021-04-27 | Astronics Aerosat Corporation | Dielectric lens for antenna system |
US10174138B1 (en) * | 2018-01-25 | 2019-01-08 | University Of Massachusetts | Method for forming highly reactive olefin functional polymers |
CN109456360B (zh) * | 2018-12-17 | 2021-05-14 | 河南中医药大学 | 一种磷丙泊酚钠的制备方法 |
WO2020156189A1 (zh) * | 2019-01-30 | 2020-08-06 | 四川科伦博泰生物医药股份有限公司 | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 |
US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
WO2021228150A1 (zh) * | 2020-05-13 | 2021-11-18 | 成都百裕制药股份有限公司 | 大麻素衍生物及其制备方法和在医药上的应用 |
TW202304524A (zh) | 2021-04-10 | 2023-02-01 | 美商普方生物製藥美國公司 | Folr1結合劑、其結合物及使用方法 |
EP4326768A1 (en) | 2021-04-23 | 2024-02-28 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2829151A (en) | 1952-11-03 | 1958-04-01 | Dow Chemical Co | Chlorotoloxy-ethyl phosphates |
US3271314A (en) | 1958-12-04 | 1966-09-06 | Ethyl Corp | 2, 6-diisopropylphenol |
GB1146173A (en) | 1966-06-18 | 1969-03-19 | Geigy Uk Ltd | Production of triaryl phosphates |
US3723578A (en) | 1970-10-13 | 1973-03-27 | Gaf Corp | Phosphate esters of ethers of thiol substituted phenols |
US4171272A (en) | 1977-12-02 | 1979-10-16 | Fmc Corporation | Turbine lubricant |
FR2601259B1 (fr) | 1986-07-11 | 1990-06-22 | Rhone Poulenc Chimie | Nouvelles compositions tensio-actives a base d'esters phosphoriques leur procede de preparation et leur application a la formulation de matieres actives. |
US5106742A (en) | 1987-03-31 | 1992-04-21 | Wall Monroe E | Camptothecin analogs as potent inhibitors of topoisomerase I |
US5364858A (en) | 1987-03-31 | 1994-11-15 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
US5122526A (en) | 1987-03-31 | 1992-06-16 | Research Triangle Institute | Camptothecin and analogs thereof and pharmaceutical compositions and method using them |
US4981968A (en) | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
US5053512A (en) | 1987-04-14 | 1991-10-01 | Research Triangle Institute | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives |
US4894456A (en) | 1987-03-31 | 1990-01-16 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
US5244903A (en) | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
US5180722A (en) | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
US5049668A (en) | 1989-09-15 | 1991-09-17 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin analogs |
US5122606A (en) | 1987-04-14 | 1992-06-16 | Research Triangle Institute | 10,11-methylenedioxy camptothecins |
MY103951A (en) | 1988-01-12 | 1993-10-30 | Kao Corp | Detergent composition |
CA2014539C (en) | 1989-04-17 | 2000-07-25 | Shinichiro Umeda | Water borne metallic coating composition |
US5091211A (en) | 1989-08-17 | 1992-02-25 | Lord Corporation | Coating method utilizing phosphoric acid esters |
JPH03209414A (ja) | 1990-01-12 | 1991-09-12 | Nikon Corp | 焦点調節装置 |
DE69027336T2 (de) | 1990-10-17 | 1996-10-24 | Tomen Corp | Verfahren und zusammensetzung zur erhöhung der aufnahme und des transportes bioaktiver wirkstoffe in pflanzen |
US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
NO310238B1 (no) | 1992-12-24 | 2001-06-11 | Bristol Myers Squibb Co | Kjemiske forbindelser og farmasöytisk preparat samt anvendelse av slike preparater |
CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
US5731355A (en) * | 1994-03-22 | 1998-03-24 | Zeneca Limited | Pharmaceutical compositions of propofol and edetate |
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
US5646159A (en) | 1994-07-20 | 1997-07-08 | Research Triangle Institute | Water-soluble esters of camptothecin compounds |
IT1270093B (it) | 1994-09-28 | 1997-04-28 | Zambon Spa | Processo per la purificazione di 2,6-diisopropilfenolo |
TW354293B (en) | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
US5804682A (en) | 1995-11-29 | 1998-09-08 | Henkel Corporation | Aqueous dispersions of polyamides |
US5637625A (en) | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
US5746973A (en) | 1996-07-10 | 1998-05-05 | Naraghi; Ali | Method for reducing odorant depletion |
DK1056754T3 (da) * | 1998-01-29 | 2004-02-16 | Bristol Myers Squibb Co | Phosphatderivater af diaryl-1,3,4-oxadiazolon |
US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
-
1998
- 1998-08-07 US US09/131,385 patent/US6204257B1/en not_active Expired - Lifetime
-
1999
- 1999-06-08 UA UA2001031520A patent/UA73479C2/uk unknown
- 1999-08-06 CN CNB998114405A patent/CN1198834C/zh not_active Expired - Fee Related
- 1999-08-06 HU HU0200317A patent/HU229401B1/hu not_active IP Right Cessation
- 1999-08-06 EP EP06004146A patent/EP1683803A1/en not_active Withdrawn
- 1999-08-06 AT AT99939030T patent/ATE319723T1/de active
- 1999-08-06 BR BR9912853-5A patent/BR9912853A/pt not_active Application Discontinuation
- 1999-08-06 PL PL347211A patent/PL198141B1/pl unknown
- 1999-08-06 AU AU53394/99A patent/AU769755B2/en not_active Ceased
- 1999-08-06 JP JP2000563666A patent/JP4554081B2/ja not_active Expired - Fee Related
- 1999-08-06 MX MXPA01001431A patent/MXPA01001431A/es active IP Right Grant
- 1999-08-06 IL IL14131699A patent/IL141316A/en not_active IP Right Cessation
- 1999-08-06 TR TR2001/00772T patent/TR200100772T2/xx unknown
- 1999-08-06 WO PCT/US1999/017779 patent/WO2000008033A1/en active IP Right Grant
- 1999-08-06 NZ NZ509795A patent/NZ509795A/en not_active IP Right Cessation
- 1999-08-06 CZ CZ20010479A patent/CZ304020B6/cs not_active IP Right Cessation
- 1999-08-06 KR KR1020017001674A patent/KR100662799B1/ko not_active IP Right Cessation
- 1999-08-06 ES ES99939030T patent/ES2268876T3/es not_active Expired - Lifetime
- 1999-08-06 DE DE69930269T patent/DE69930269T2/de not_active Expired - Lifetime
- 1999-08-06 DK DK99939030T patent/DK1102776T3/da active
- 1999-08-06 RU RU2001106614/04A patent/RU2235727C2/ru not_active IP Right Cessation
- 1999-08-06 EP EP99939030A patent/EP1102776B1/en not_active Expired - Lifetime
- 1999-08-06 CN CNA2005100524949A patent/CN1680402A/zh active Pending
- 1999-08-06 PT PT99939030T patent/PT1102776E/pt unknown
- 1999-08-06 CA CA2339834A patent/CA2339834C/en not_active Expired - Fee Related
-
2000
- 2000-12-08 US US09/733,817 patent/US6451776B2/en not_active Expired - Lifetime
-
2001
- 2001-02-07 ZA ZA200101039A patent/ZA200101039B/en unknown
- 2001-02-07 NO NO20010659A patent/NO330357B1/no not_active IP Right Cessation
-
2002
- 2002-07-29 US US10/208,647 patent/US6872838B2/en not_active Expired - Fee Related
-
2003
- 2003-01-02 HK HK03100006.9A patent/HK1047939B/zh not_active IP Right Cessation
-
2004
- 2004-11-17 US US10/991,348 patent/US7244718B2/en not_active Expired - Fee Related
-
2006
- 2006-06-02 CY CY20061100710T patent/CY1105043T1/el unknown
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7576127B2 (en) | 2003-09-09 | 2009-08-18 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
US20050107385A1 (en) * | 2003-09-09 | 2005-05-19 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
US20060287525A1 (en) * | 2003-09-09 | 2006-12-21 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
US7230003B2 (en) | 2003-09-09 | 2007-06-12 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
US20080248093A1 (en) * | 2003-10-24 | 2008-10-09 | Auspex Pharmaceuticals, Inc. | pH sensitive prodrugs of 2,6-diisopropylphenol |
US7691904B2 (en) | 2003-10-24 | 2010-04-06 | Auspex Pharmaceuticals, Inc | pH sensitive prodrugs of 2,6-diisopropylphenol |
US20090005352A1 (en) * | 2004-07-12 | 2009-01-01 | Xenoport, Inc. | Prodrugs of Propofol, Compositions and Uses Thereof |
US20060100160A1 (en) * | 2004-07-12 | 2006-05-11 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
US20060041011A1 (en) * | 2004-07-12 | 2006-02-23 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
US7241807B2 (en) | 2004-07-12 | 2007-07-10 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
US7645792B2 (en) | 2004-07-12 | 2010-01-12 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
US7550506B2 (en) | 2004-07-12 | 2009-06-23 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions and uses thereof |
US20060205969A1 (en) * | 2004-12-23 | 2006-09-14 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
US7619110B2 (en) | 2004-12-23 | 2009-11-17 | Xenoport, Inc. | Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
US20080234229A1 (en) * | 2005-08-18 | 2008-09-25 | Auspex Pharmaceuticals, Inc. | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
US7589239B2 (en) | 2005-09-02 | 2009-09-15 | Auspex Pharmaceuticals | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders |
US20080221069A1 (en) * | 2005-09-02 | 2008-09-11 | Auspex Pharmaceuticals, Inc. | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
EP2292577A1 (en) | 2007-05-09 | 2011-03-09 | Pharmacofore, Inc. | (+)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof |
EP2301908A1 (en) | 2007-05-09 | 2011-03-30 | Pharmacofore, Inc. | (-)-stereoisomer of 2,6-di-sec-butylphenol and analogs thereof for promoting antiemetic effect and treatment of nausea and vomiting |
EP2392559A1 (en) | 2007-05-09 | 2011-12-07 | Pharmacofore, Inc. | Therapeutic compounds |
EP2810927A1 (en) | 2007-05-09 | 2014-12-10 | Sowood Healthcare LLC | Therapeutic compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6451776B2 (en) | Water soluble prodrugs of hindered alcohols | |
US7534776B2 (en) | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol | |
ES2710380T3 (es) | Compuestos y usos de los mismos para la modulación de hemoglobina | |
AU697856B2 (en) | Brefeldin A derivatives and their utility in the treatment of cancer | |
ZA200404423B (en) | Genes encoding for carbon metabolism ad energy producing proteins | |
CN116583529A (zh) | 阿比特龙衍生物及其制备方法 | |
EP0532328A2 (en) | Novel lignans, intermediates thereof and a process for preparing the intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: UNIVERSITY OF KANSAS, KANSAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STELLA, VALENTINO J.;ZYGMUNT, JAN J.;GEORG, INGRID GUNDA;AND OTHERS;SIGNING DATES FROM 19980908 TO 19980928;REEL/FRAME:024957/0695 |
|
FPAY | Fee payment |
Year of fee payment: 12 |